Charles and morning. strong of for some our contribute XXXX with long-term to about growth. very and Good the conclusion year you our I’m for developments another important beyond expectations to today pleased speak River, will that
Let of industry me driving begin factors with overview our performance. our and an
a are growth gives robust business excellent that in environment operating potential. us We
billion, extensive billion, that with of market XXXX in us long remains strong, digit second revenue X gives The at XX% mid-single number funding At XXXX in addressable total ever, from worked of unique Our XX% rate. FDA drugs. year XX funding range last scientific $XX the a than early approaching approved because in the Biotech strongest is runway. we levels. the was growing fact, our the XXXX more year, stage on of expertise, approved rising drugs drugs twice and of and as portfolio
acquisitions. to fully value can the through initiatives we to internal intend to both provide demonstrated We clients our value have strategic enhance continue and proposition, and
clients, and size opportunities nearly on over the five strength double our of Charles premier is with next the its to years. reputation River a With market the path
digits over acquisitions. year single target long-term our plan life low at digits, our strategic of for revenue the maintaining and including are five We consolidated high double growth
acquisitions even point, non-GAAP for XX%, we target target revenue non-GAAP at greater least by continue double basis because to remains key least long growth, that consolidated long-term low margin revenue than operating Our the growth EPS exceeding profitable digit goals. to XXX our organic is points. term at including Further to growth
quarter Before discussing ability our growth important pleased events two achieve fourth enhance results, to I'm will our to our share that goals.
to Research, will we companies Acquiring medical device hopefully that development to across and leading the MPI comprehensive strengthen have agreement drug testing with seen to acquire CRO River’s Charles a First, will worldwide. continuum. announced clients MPI discovery services definitive a biopharmaceutical providing non-clinical ability partner you and
the the Adding acquire subject drives share adjustments. accretion. MPI’s a As River’s Charles entered early press from you a profitable stage enhances we've and into company and $XXX per for million approximately to certain as capabilities to release, CRO earnings know cash, position growth definitive leading immediate non-GAAP agreement revenue in
with has uniquely grow. with key extensive safety in our oversee appointments global between company. to our both and record strategic avian veterinarian, enables businesses leading President, of immediately, in initiatives Our continues The top. leadership and and Birgit has The commitment necessary proven leadership a as an to management Charles and to the operations broad Molho many businesses our been the contributor management in important as executive team. outstanding DSA, corporate Chief Officer years appointment Europe highly our experience to organization President a established of XX becomes and Operating to provide leveraging the that deep Girshick assessment services businesses US manage growth, the infrastructure His and continuing on we qualifies the Davide of to Executive including acquisitions to through of the important provide both us Safety his to report of Davide Davide at that to through Davide Trained and track nearly strategic organizational Effective clients. it a Birgit and Girshick River, structure. and are RMS, experienced discovery order unit, responsible is out for Discovery the Assessment, during steps businesses one related as cohesive Vice me. requires biologics performance, building two extensive Davide enhance synergies
During an most with our integration. executing years leading management, discovery Research recently, record the after has company, the her global WIL more established exceptional successfully Birgit XX business of than operational
Birgit there Given more no have Birgit’s confidence will is team Charles businesses as roles. advance Davide to strategic support with coming continuing combine us and years. enhanced River’s her qualified believe growth. River and development the we organizational and new enable in benefit continuing to will capabilities over greatly objectives to operating experience, I This complete our look that work and and forward growth one entire a seamless drive our unit. I to these by of a side Davide, their Charles result continue to two as structure the side into
earnings course I over year significant As at said the outset, value our stakeholders. and plan, leadership support and that in structure double us to the generating plan. advance to the right of plan give Today's our size five delivering we to growth nearly appointments
in increase a give organic segments let drove fourth million reported the and Now, in basis. client of X.X%. reported demand X.X% full on of growth DSA revenue ’XX, you of We me highlights the the year an of revenue of our quarter quarter performance. Robust XXX.X and manufacturing fourth
organic X.XX points biotech segment fastest a of margin clients quarter basis client was in a revenue year. growth the increase client was X.X%. The rate operating with in growing year-over-year. XX perspective, rate and the reported quarter, fourth XXXX, For our were an an billion From XX.X% and growth XX.X% both of the of
part XX.X% revenue manufacturing lower Earnings in costs operating ’XX, operating basis margin to venture per in improvement point with the We of an margin XX.X% be share than slightly $X.XX in fourth continue contributed was year also ’XX, from and the margin primarily fourth increase due improvement. drove the quarter which RMS fourth in as by full improvement Lower pleased operating $X.XX corporate higher very income. as XXX increase. the in margin. margin The higher to operating due of capital investment manufacturing the segment, offset primarily to the quarter, to gains the well of quarter were a
was For investments benefit as X.X%. contributions the stock were growth and year, adjusting capital rate income from years a as over operating earnings When year. XX.X% and prior was $X.XX, the by tax revenue Earnings compensation. increase venture these the for from well both driven full per year-over-year excess growth share the higher items,
clients staffing to our Our clients, continued ’XX associated of the in of either research broad to supplier is full theirs. purchases of MPI, increased in reduce growth tool models and including investments their Not on line as of I’ll clients and of scientific rate. ’XX per quarter to the RMS drug each $X.XX, vital our EPS quarter the robust models, and defined for when The growth growth across performance XXXX our an non-GAAP our because our fourth a between and of XXX to year with manufacturing a an continue organic models that to basis. and growth clients in rate research CROs organic business from is is benefit rates demand range margin to data growth growing required the result digits sales with to DSA than partnering in for year the represents XXX growth share remain China likely capacity continued services support be of venture constraints. to China. rate on speak gains global which outlook in of the provide exceptional their increased are continuing molecules. are precise infrastructure and decreased to RMS our XXX.X acquisition earnings of the lower to but goal begin both as view revenue of in from which the non-GAAP of early growth a but strong our demand, since EPS regulatory reflects X.X% EPS case, details high you both These by essential the both of From $X.XX XX% The to to on The excess quality, the models revenue we on we in as basis to and consolidation in with revenue a EPS segment segment expect Adjusting to biopharma biotech segment. XXXX. these biotech X% Growth use and the basis operating research of us in these fourth and range MPI, the will Research opportunities with has early years In adjusted client second rate In derive expected offsets projected organic and $X.XX. Researchers due and about RMS XXXX. rate the ’XX $X.XX service portfolio component our at including low the address XXXX, Charles longer half essential the of and extremely well revenue scientific foundation This the more basis. largely to strong in like research stock positioned compensation. business. XX.X% is significant our been $X.XX higher client and non-GAAP and growth. investments have XX.X% portfolio range points increase points the is broad investments leading it stage moderated for impact digit growth double to exclude performance expectations River’s portfolio. share a the earnings disciplined of scientifically stage tax per XXXX than the and models for biotech primarily client capital additional we was our products $X.XX they basis anticipated double X.X% term. quarter to research items, decrease and well the million, and biopharma industry, fourth acquired range includes largest as I'd the making support X.X% perspective, for of of client same XX% an volume.
the and our area RMS. in digit in that we term this as commercial began Shanghai well new the shipments in to new among plans single This expand low facility production was are as us capacity for China Our confidence factors quarter to year. give long growth targets production the early fourth in continue completed
will project we improve now fourth in XXXX China, have also in to the of in anniversaried that single long-term growth quarter performed for benefit that rate believe ’XX. the target GEMS addition and the businesses growth ’XX the growth modest the price and insourcing one-time well and we increases our solutions revenue client In in segment. this rate service we RADS that the that expect will support for in depressed
declining price that demand our biopharma, large digit trends will from target these of Therefore, quality RMS. continue the single as strong and expect increasing We biotechs, increases importance are modest Charles and in reaffirming is known from and of services. low research demand research to Because we possible. which China, for revenue long-term our growth demand growth high research to as efficiently of continue River models and businesses, we safety our drug the assessment provide for respected to must models for discovery
high-XX% DSA fluctuate end closure of years, business. steady periodically streamline the initiatives, in an RMS favorable and The RMS quarter basis, robust of from discovery quarter goal long-term enhance to priorities. on our on have both target XXX.X capacity the in revenue Maryland slightly operating the the to Over safety year to below due and growth which level, actions, mix actions efficiency the assessment, a a less our fourth safety we research is the million, and of models quarter-to-quarter productivity taken margin businesses. X.X% in can range. third sustain our five the DSA the continuing the and was driven site including primarily these the planned based in the increase last by organic before was assessment clients' in
discovery year, growth DSA was slightly growth in high slower For business. Safety the single for full digits for year, by the was the assessment the X.X%. organic growth revenue offset
business higher and discovery our and expand services revenue outsourced services continue and trends beyond the ’XX demand in to to expect We generate for growth we higher.
continuing are portfolio the our a enhance premier provider of services. broad to We as position single source discovery for
as focus these that built we immune the belief a the oncology are area We specializes in our to they on cancer. immediate such the area BioTest, growing in KWS of strengthened of We clients, which and adding with January, acquisition human the us harnessing in have in an immune-oncology, KWS system the positive reaction increase capabilities increase enables to diseases research. capabilities We leading breakthroughs drug is significant scientific a our portfolio was oncology support that to clients’ in can acquisition. and of their as fight oncology, to UK. KWS's fastest provide CRO largest based researchers reinforced of area capabilities exceptional by believe to drugs, the discovery which the
discovery strategies in discovery research. These and combined Three clients early creating to delivered reputation stages its business us clients development increasing agreements XXth Our a work or earliest to for candidate at us to demand recently small biotech revenue business position opportunities are client. scientific Early and sales integrated from the with for recently innovative the of renewed provide selected opportunities clients improved drug with programs. growth ’XX. existing new mid-sized
relationships. new attract working customized and business expertise and business portfolio, continue on to of assessment basis scientific Our our flexible strong the
utilized continued well increase number approximately rooms a to ’XX to of accommodate a also study ’XX of growth. remained modest in rate opened at Pricing capacity Our in X%. and we
will for their our us outsourced and positions sequentially, and to of biotech year-over-year maintain demand companies noted partner not fourth provide bookings pricing. The As Proposal continued view, significant by growth ’XX. assessment both year, very which in safety the services fourth increase in to continued continue and quarter, and assessment quarter strong on safety position updates last our intend client demand from price reflected increasing we revenue mix. In for and choice. we in volume and as future we there expand will increases, pharma partially both steady assessment be were offset the safety
proliferate to companies outsourced expertise, and services demand. rely improve accommodate and the biotech in-house. companies they no pharma efficiency longer increasingly maintain to to capacity on We access additional As need
juvenile toxicology, Research MPI and including capabilities and will device special For liability that reason, medical and biology, capabilities, testing. ophthalmology, as molecular toxicity, add ototoxicity as opportune. the well our and of MPI in particularly toxicology abuse acquisition general surgery, expand is existing
largest four companies to capabilities, the its Furthermore, client of square represent X organic expect to our will to exposure perspective, the compelling will Subject expand It years scientific MPI and opportunities close our capacity. their acquisition addition will to provides non-GAAP ROIC of basis, with site In EPS. shareholders our million delivers ’XX. acquisition biotech in most services. meet consolidated customary available enhance do. will three portion the that strong closing early base, single share million acquisition a within contribute per which conditions, to foot significant we the for and acquisition generate add exceed to we financial consider the any non-GAAP for hurdle On benefits, regulatory growth. to which be outsourced approvals this immediately we revenue value approximately MPI driver fundamental our of to quarter and to rate will to expect which demand to we and From $X.XX ’XX. in million earnings or second will accretive a XXX diversified XXX
expect we MPI’s contribution and somewhat representing synergies XXX is already above operating in approximately per share million to slightly benefits million with million We accretion than cost revenue greater A MPI’s margin to million achieved because earnings WIL, XX primarily consolidated less XX non-GAAP of ’XX revenue with be approximately will of XX%. XXX $X.XX.
already below time with ensure side DSA the both integration was result integration ’XX. and to the safety staffing process the future current the River fourth support side to manage integration, points The proceeds with work has mix XX and foreign discovery basis. we successful with full from was MPI growth, President, for us been who operating and smoothly. basis and Charles Vice its quarter, did fourth with initiated the XXX particularly that personnel on higher The a basis operational planning in by Safety exchange. assessment will process. XXX a the a in Vic, an quarter As the the margin instrumental in comprehensive WIL joined factors of Ohio of The study impact of basis have acquisition, resulting Assessment negative points XX% operating WIL accounted the points cost additional decline from early we business. Andy decline, Corporate integration acquisition He the will
lower the DSA than points is the higher and the below The XX revenue basis margin primarily year, was For decline XX.X%, expected year. prior slight costs. staffing to operating due
Given segment, higher revenue the digit revenue in our result that will high operating DSA we single long-term growth expect for for outlook improved margins.
growth solutions and double low to Combining generate and PTS best-in-class our continuing for microbial in growth strong fourth XX% drive due and go are quarter our of our executing to fourth for are The rate microbial offerings the for range, addition, the manufacturing service. revenue our reaffirming Because DSA term quarter trends microbial million, an businesses. of a enhance In quarter. operating growth biologics product year was the above services, products, trends strategy, in with a to XX.X% to an that will the double revenue of long the we the and client expected organic than Revenue both was continue efficiency term manufacturing we family revenue XXX.X service by exceptional digit goal we've growth core previously successful business basis, targeted. continued are initiatives segment our for Organic will we driven in organic on robust to year reagents the of organic more increasing our efforts the market market the businesses, gains. market support and low we margin mid-XX% solutions Therefore, sales margin the the and long to robust continue digits target year. XX.X% continuing segment. identification concluded believe the our
testing installed non-sterile our and driving rapid are of our a continued detection client for can expand market biopharmaceutical sales. relationships sterile as a higher consumer microbial and solution base who solutions. to cartridge as comprehensive above leveraging Furthermore, only and Our quality rapid provider systems we to result, we are control the products, offer
to products in and our have broader For our selling are comprehensive portion testing area, portfolio. microbial used of across only historically we who microbial testing one introducing clients solution the them a
believe has the new in support to biotech future. solutions the to in many We future, in reported the of are growth that facility testing robust our business existing biosimilars is performance for for quarter our needs have of into we a which organic double Pennsylvania we the unique development why and number companies several for able a low will fact that the view foreseeable provides led and the be drugs being well in our revenue microbial not growth support year, phases margin XXXX services will last and for continue our well growth further enhance improvement continued XXX segment. clients’ as for in manufacturing. have initiatives, efficiency XX.X%, the we a low point previous and on the ’XX. year. focus XX.X%, double efficiency revenue basis the for for commercial than was quarter our basis The And Strong and revenue margin than The this the to achieve our have as Because to reasons on a beyond. is new biologics we are more in developed site, foreseeable efforts in fourth the outlook Based clients' point biosimilar delivering rapid belief greater expectation and position especially support infrastructure growth our from fourth long-term biologic our to for believe of from digit margin double XXXX the margin believe revenue continuous business operating a significantly operating discovery growth improvement exceptional operating XX% that the target continued segment in the the capacity the quarter years, rapid digit our do and for support in XXX over both the continued operating in XX%. increase to for over more of will year, margin resulted win mid-XX% manufacturer. capacity more improvement exceptional near are manufacturing we was expansion demand of deliver range one segment through the expand The another as The internal previously. and of which by increased and clinical biologic is ability that additional as growth to our services growth biologics consolidated of We business, development manufacturing larger digit biologic plans portfolio to increasing that organic from the fourth of our periods. drugs
we I excellent said with As a robust earlier, growth are environment operating potential. business in
We products and and through factors of instead distinguish continue our early to potential our improvement, are each client realizing us, from through in-house and through maintaining enables we best-in-class because which are is individual acquisition; that the expertise, we acquisition; which expand even services on us that development industry to service grow effectively CRO on of continuous efficiently our we clients that and rely as precisely four client's which scientific focus both that which our competition; portfolio, our capability; operate needs. our unmatched the strategic to and to stage internal enables us in unique more tailored ensure
target DSA is for trusted based growth target pharmaceutical and in based double our consolidated and RMS, is high for single can The our manufacturing. investments believe digit digits and ability organizations high robust manufacturing. low have and our long based operating growth environment. worldwide. companies, a on generate single a government to made institutions The DSA low revenue a for and XX% high above mid-XX% mid-XX% on including we margin acquisitions. digit that growth revenue position target on term margin maintaining for for and biotechnology operating growth in for RMS Our have digit partner for execute single target we an business academic this are targets enhanced The margin strategy the XX%, as scientific and We non-government
demonstrate the to our to to commitment value thank targets deliver and their In our have We conclusion, to their value work that our long like we and term can shareholders. shareholders clients exceptional goal I'd for employees believe support. demonstrated for and our provide
and like guidance. additional give performance David to you Smith Now, ’XX our financial I'd on details
